Results 121 to 130 of about 1,666 (186)

Increasing β-hexosaminidase A activity using genetically modified mesenchymal stem cells. [PDF]

Neural Regen Res
Shaimardanova AA, Chulpanova DS, Solovyeva VV, Issa SS, Mullagulova AI, Titova AA, Mukhamedshina YO, Timofeeva AV, Aimaletdinov AM, Nigmetzyanov IR, Rizvanov AA.   +10 more
europepmc   +1 more source

The role of sphingolipids in heart failure. [PDF]

Eur Heart J Open
Hamouche R, Summers SA, Holland WL, Navankasattusas S, Drakos SG, Tseliou E.   +5 more
europepmc   +1 more source

CLN5 : from mutation to defective protein and clinical phenotype [PDF]

, 2004
Holmberg, Ville
core  

Animal models of GM2 gangliosidosis: utility and limitations [PDF]

core   +2 more sources

Lysosomal free sialic acid storage disorder iPSC-derived neural cells display altered glycosphingolipid metabolism. [PDF]

Sci Rep
Sabir MS, Jovanovic VM, Ryu S, Sen C, Ormanoglu P, Pollard L, Steet R, Gahl WA, Huizing M, Tristan CA, Platt FM, Malicdan MCV.   +11 more
europepmc   +1 more source

Gangliosides in molecular interactions and cell regulation. [PDF]

J Biol Chem
Mlinac-Jerkovic K, Heffer M, Schnaar RL.
europepmc   +1 more source

In Vitro Studies Of Liposome Carriers In Enzyme Replacement Therapy Of Feline Gangliosidoses. [PDF]

, 1978
Reynolds, Gary Dean
core   +1 more source

Linking glycosphingolipid metabolism to disease-related changes in the plasma membrane proteome. [PDF]

Biochem Soc Trans
Monkhouse H, Deane JE.
europepmc   +1 more source

Plasma Membrane Remodelling in GM2 Gangliosidoses Drives Synaptic Dysfunction

Nicholson AS, Priestman DA, Antrobus R, Williamson JC, Bush R, Barrow HG, Smith E, Dobrenis K, Bright NA, Platt FM, Deane JE.   +10 more
europepmc   +1 more source

Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders. [PDF]

Mol Ther Methods Clin Dev
Zhou L, Wang Y, Xu Y, Zhang Y, Zhu C.
europepmc   +1 more source